Abstract
Chronic myeloid leukemia (CML) develops as a result of a clonal process in a pluripotent stem cell. Anemia, granulocytosis, basophilia, thrombocytosis and splenomegaly are some of the symptoms of the condition. According to clinical findings, the illness progresses through three stages, each of which is identified by a rise in number of the blast cells in peripheral blood or bone marrow: chronic (10%), accelerated (10-19%) and acute leukemia-like blast crisis (20%). Most CML cases could be preliminary diagnosed by the presence of splenomegaly in addition to mutation in the BCR-ABL gene as well as complete blood count (CBC) test. Moreover, a bone marrow biopsy can provide a major confirmation of the disease process and staging. Definitive diagnosis of the disease can be either achieved through fluorescence in situ hybridization (FISH) or polymerase chain reaction PCR technique.
References
Alameri, A. Al-khudhair, M., Batool, G., Al-Mudhafer, A., Murad, N. (2009). Epidemiology of chronic myeloid leukemia in Iraqi patients. 14th Congress of the European Hematology Association Abstract Book haematologica, 94(s2), p 578.
AL-Yasiri,Y.A.H. (2011). Molecular study of BCR-ABL gene and genetic variations in chronic myeloid leukemia patients in Iraq. Master thesis. College of Science. AL-Nahrain University.
Bollmann, P.W., Giglio, A. (2011). Chronic myeloid leukemia: past, present, future. Einstein, 9 (2 Pt 1): 236-43.
Boylu, C.A. (2004). Analysis of candidate molecular targets in adult (CML) and childhood (AML, ALL) leukemias. PhD dissertation. Bilkent University.
Dolinska, M. (2019). Understanding the role of bone marrow niche in myeloid malignancies. Ph.D thesis, Karolinska Institutet, Stockholm, Sweden.
Eden, R.E., Coviello, J.M. (2022). Chronic myelogenous leukemia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 30285354.
El Bahy, A.R.A. (2012). Prognostic factors in Chronic Myeloid Leukaemia therapy. MD (Res) thesis. Imperial College London.
Faderl, S., Talpaz, M., Estrov, Z., Kantarjian, H.M. (1999). Chronic Myelogenous Leukemia: Biology and Therapy. Ann Intern Med., 131, 207-219.
Fentie, A.M., Woldu, M.A., Worku, B.A. (2017). Current management approaches of Chronic Myeloid Leukemia. J Cancer Sci Ther, 9(8), 595-607.
Furtado, V.F., Santos, G.R., de Carvalho, D.S., Staziaki, P.V., Pasquini, R., Funke, V.A.M. (2015). Accelerated phase chronic myeloid leukemia: evaluation of clinical criteria as predictors of survival, major cytogenetic response and progression to blast phase. Rev Bras Hematol Hemoter., 37(5):341–347.
Granatowicz, A., Piatek, C.I., Moschiano, E., El-Hemaidi, I., Armitage, J.D., Akhtari, M. (2015). An overview and update of Chronic Myeloid Leukemia for primary care physicians. Korean J Fam Med, 36,197-202.
Gunnarsson, N. (2017). Chronic myeloid leukemia and cancer. PhD Dissertation . Umeå University Umeå, Sweden.
Guo, J. Q., Lin, H., Kantarjian , H., Talpaz, M., Champlin, R., Andreeff, M., Glassman, A., Arlinghaus, R.B. (2002). Comparison of competitive-nested PCRand real-time PCRin detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients. Leukemia, 16: 2447–2453.
Hamad, Y. M. K. 2019. Incidence of Chronic Myeloid Leukemia: Systematic Review and Meta-analysis. Master thesis. College of health sciences. Qatar University.
Hillman, R.S., Ault, K.A., Leporrier, M., Rinder, H.M. (2010). Hematology in clinical practice (5th Ed.), McGraw-Hill Companies.
Hochhaus, A., Saussele, S., Rosti, G., Mahon, F.X., Janssen, J.J.W.M., Hjorth-Hansen, H., Richter, J., Buske, C. (2017). ESMO Guidelines Committee. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 1, 28 (suppl_4):iv41-iv51.
Hoffbrand, A.V., Vyas, P., Campo, E., Haferlach, T., Gomez, K. (2019). Color atlas of clinical hematology Molecular and Cellular Basis of Disease (5th Ed.). John Wiley & Sons Ltd.
Jabbour, E. Kantarjian, H. (2018). Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol, 93,442–459.
Kaushansky, K., Prchal,J. T., Press, O.W. Lichtman, M.A., Levi, M., Burns, L.J. Caligiuri, M.A. (2016). Williams Hematology. McGraw-Hill Education.
Kuan, J.W., Su, A.T., Leong,Ch. F., Osato, M., Sashida, G. (2018). Systematic review of pre-clinical chronic myeloid leukaemia. International Journal of Hematology, 108(5),465-484.
Kumar, N., Ahluwalia, J., Malhotra, P., Sachdeva, M.U.S. (2013). Chronic lymphocytic leukemia developing in a case of chronic myelogenous leukemia - accelerated phase: A rare case with review of the literature. Indian J Pathol Microbiol, 56(3): 303-305.
Lavrov, A.V., Chelysheva, E.Y., Smirnikhina, S.A., Shukhov, O.A., Turkina, A.G., Adilgereeva, E.P. Kutsev, S.I. (2016). Frequent variations in cancer-related genes may play prognostic role in treatment of patients with chronic myeloid leukemia. BMC Genetics , 17(Suppl 1),14.
Longo, D.L. (2017). Harrison’s tm hematology and oncology (3rd Ed.), McGraw-Hill Education.
Lyengar, V., Shimanovsky, A. (2021). Leukemia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.
Meng, Ch.Y. (2001). Cytogenetics and molecular studies in chronic myeloid leukemia. PhD dissertation. St Clements University.
Mjalia, A., Abbas, S.K. (2021). Imatinib mesylate adherence in Chronic Myeloid Leukemia patients: Data from Middle Euphrates Region of Iraq. Sys Rev Pharm, 12(1),83-87.
Mondal, J.D., Tewary, D., Sardar, S.M. (2014). Chronic Myeloid Leukemia – An Overview. IJSR, 3(1),128-132.
Musselman, J.R., Blair, C.K, Cerhan, J.R., Nguyen, P., Hirsch, B., Ross, J.A. (2013). Risk of adult acute and chronic myeloid leukemia with cigarette smoking and cessation. Cancer Epidemiol, 37(4), 410-6.
Naeim, F., Rao, P.N., Phan, R.T. (2018). Atlas of Hematopathology Morphology, Immunophenotype, Cytogenetics, and Molecular Approaches (2nd Ed.). Academic press.
Navas, V., Simancas, D., González, L.E., Hidalgo, R., Cardona, A.F., Martí-Carvajal, A.J. (2010). Imatinib for treating patients with chronic myelogeneous leukemia. Cochrane Database of Systematic Reviews,1, CD008259.
Niederhuber, J. E., Armitage, J.O., Doroshow, J.H., Kastan, M.B., Joel, E. Tepper, M.D. (2014). Abeloff's Clinical Oncology (5th Ed.). Faculty Bookshelf.
Quintás-Cardama, A. Cortes, J. (2006). Chronic Myeloid Leukemia: diagnosis and treatment. Mayo Clin Proc., 81(7), 973-98.
Russo, D., Garcia-Gutierrez, J.V., Soverini, S., Baccarani, M. (2020). Chronic Myeloid Leukemia prognosis and therapy: criticisms and perspectives. J. Clin. Med., 9,1709.
Söderlund, S. (2017). Clinical and immunological studies in Chronic Myeloid Leukaemia. Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, 1347.
Thompson, Ph.A., Kantarjian, H., Cortes, J.E. (2015). Diagnosis and Treatment of Chronic Myeloid Leukemia (CML) in 2015. Mayo Clin Proc., 90(10), 1440–1454.
Turgeon, M.L. (2012). Clinical Hematology Theory and Procedures (5th Ed.), Lippincott Williams & Wilkins.
Vardiman, J.W. (2009). Chronic Myelogenous Leukemia, BCR-ABL1+, Am J Clin Pathol, 132,250-260.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright (c) 2023 Array